| Over a week ago | ||||
H.C. Wainwright analyst… H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on Repligen to $225 from $168 and reiterates a Buy rating on the shares. The analyst continues to expect "durable" demand for bioprocessing services in 2020 and beyond, saying COVID-19 vaccines are likely to become long-term franchises due to the ongoing virulence of the pandemic and the rise of novel variants of the SARS-CoV-2 coronavirus. Repligen could exceed $1B in revenue by 2026 through organic growth alone, Selvaraju tells investors in a research note. | ||||
| Over a month ago | ||||
Virtual Meeting to be… Virtual Meeting to be held on March 8 hosted by KeyBanc. | ||||
Craig-Hallum analyst Matt… Craig-Hallum analyst Matt Hewitt raised the firm's price target on Repligen to $251 from $245 and keeps a Buy rating on the shares. The analyst notes that results and guidance surprised to the upside in Q4, and COVID-19 tailwind appears to only be getting stronger. | ||||
SVB Leerink analyst… SVB Leerink analyst Puneet Souda raised the firm's price target on Repligen to $250 from $220 and keeps an Outperform rating on the shares. The analyst notes that Repligen delivered another "impressive" quarter. | ||||
Sees 2021 revenue… Sees 2021 revenue $500M-$525M, consensus $459.53M. | ||||
Reports Q4 revenue… Reports Q4 revenue $108.6M, consensus $93.88M Tony Hunt, President and CEO said, "We are delighted with the way we finished off 2020 with 47% organic growth in the fourth quarter and 29% for the full year. Sales into COVID vaccine and therapeutic accounts were a major contributor to overall growth especially in the second half of 2020. Our non-COVID markets also performed well, up over 18% in 2020. All our franchises delivered robust growth during the year, and we continued to see traction at gene therapy accounts. Strategically, our three acquisitions position us well to accelerate growth in our systems and fluid management businesses in 2021. With a very strong order load and COVID tailwinds, we anticipate that 2021 will be another excellent year for the company as we build additional manufacturing capacity, support the manufacturing of COVID vaccines and therapeutics and launch exciting new products." | |
Repligen and Navigo… Repligen and Navigo Proteins, a protein engineering company specializing in novel affinity ligand development, have completed the development and initiated the commercial launch of NGL COVID-19 Spike Protein Affinity Resin, a novel affinity resin to be utilized in the purification of COVID-19 vaccines. This COVID-19 affinity resin is the result of an accelerated program to provide COVID-19 vaccine manufacturers with a high purity capture step, decreasing processing time and significantly improving overall yield in the production of these critical vaccines. NGL COVID-19 Spike Protein Affinity Resin will be manufactured and marketed by Repligen. Resin samples are available immediately. |
| Over a quarter ago | ||||
Craig-Hallum analyst Matt… Craig-Hallum analyst Matt Hewitt raised the firm's price target on Repligen to $245 from $229 and keeps a Buy rating on the shares. The analyst notes that commentary from customers, competitors, and Repligen itself overwhelmingly points to another strong year for the company. | ||||
The deal priced below the… The deal priced below the last closing price of $185.91. JPMorgan and Stifel are acting as joint book running managers for the offering. | ||||
J.P. Morgan Securities… J.P. Morgan Securities LLC and Stifel, Nicolaus & Company, Incorporated are acting as joint book-running managers for the offering. Craig-Hallum Capital Group, Stephens Inc., SVB Leerink LLC and William Blair are acting as co-managers for the offering. | ||||